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Background: The use of growth-promoters in beef cattle, despite the EU ban, remains a frequent practice. The use
of transcriptomic markers has already proposed to identify indirect evidence of anabolic hormone treatment. So far,
such approach has been tested in experimentally treated animals. Here, for the first time commercial samples were
analyzed.
Results: Quantitative determination of Dexamethasone (DEX) residues in the urine collected at the slaughterhouse
was performed by Liquid Chromatography-Mass Spectrometry (LC-MS). DNA-microarray technology was used to
obtain transcriptomic profiles of skeletal muscle in commercial samples and negative controls. LC-MS confirmed the
presence of low level of DEX residues in the urine of the commercial samples suspect for histological classification.
Principal Component Analysis (PCA) on microarray data identified two clusters of samples. One cluster included
negative controls and a subset of commercial samples, while a second cluster included part of the specimens
collected at the slaughterhouse together with positives for corticosteroid treatment based on thymus histology and
LC-MS. Functional analysis of the differentially expressed genes (3961) between the two groups provided further
evidence that animals clustering with positive samples might have been treated with corticosteroids. These suspect
samples could be reliably classified with a specific classification tool (Prediction Analysis of Microarray) using just
two genes.
Conclusions: Despite broad variation observed in gene expression profiles, the present study showed that
DNA-microarrays can be used to find transcriptomic signatures of putative anabolic treatments and that gene
expression markers could represent a useful screening tool.
Keywords: DNA-microarray, LC-MS, Anabolic treatment, Cattle, Skeletal muscle, UrineBackground
The use of growth promoters in meat production has been
banned in the European Union since 1988 due to the po-
tentially adverse effects of hormone residues for the con-
sumer. Council Directive 23/96/EC requires the EU
member States to adopt National Monitoring Plans to con-
trol the illegal use of these compounds. Despite the ban,
these substances are still administered and a black-market
for the production, distribution, and use of multiple ster-
oids has flourished [1]. To elude official controls, new* Correspondence: clara.montesissa@unipd.it
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Padua, Viale dell’Università 16, 35020, Legnaro, Padova, Italy
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reproduction in any medium, provided the oranabolic compounds are developed and growth promoters
are administered at low doses or combining different sub-
stances in hormone cocktails. To keep pace with such a
moving target, constant innovation in screening and valid-
ation methods is necessary.
Anabolic steroids act on multiple organs and metabolic
pathways either through primary interaction or secondary
effects. For this reason, indirect approaches, based on the
evaluation of perturbations of different biological systems,
have been proposed to identify growth-promoter-treated
animals. Target organ histology, transcriptomics, proteo-
mics, and metabolomics have been explored as screening
tools to better inform confirmative analysis [2-5]. TheLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Pegolo et al. BMC Veterinary Research 2012, 8:205 Page 2 of 13
http://www.biomedcentral.com/1746-6148/8/205application of transcriptomics in toxicology has experi-
enced an impressive growth in recent years, leading to the
foundation of a new discipline, toxicogenomics [6]. Al-
though toxicogenomics has mostly focused on the effects
of pharmacological compounds in model species, it is in-
creasingly applied to monitor the effects of xenobiotics in
non-model species (e.g. eco-toxicogenomics). In this con-
test, gene expression profiles have been used to obtain in-
direct biomarkers for the use of growth promoters in beef
meat production. Initially, quantitative real-time PCR was
used to analyze the expression of candidate diagnostic
genes. This approach has already been successfully applied
in several studies on experimentally treated animals [7-12].
However, good candidate genes are often difficult to iden-
tify and the use of single or few gene markers provides a
limited and biased view of the biological response to xeno-
biotics. Using either DNA microarray platforms or RNA-
sequencing, it is possible to obtain whole-transcriptome
expression profiles, which provide a broad and unbiased
(hypothesis-free) picture of the biological response to toxi-
cants. Thanks to the decreasing costs of genomic technolo-
gies, transcriptomics is starting to be applied to the
identification of gene markers for anabolic treatments in
beef cattle. Microarray analysis has been used so far to
examine the effects of anabolic hormones in experimen-
tally treated animals, as in the case of skeletal muscle sam-
ples from bulls administered with Dexamethasone (DEX)
and DEX plus 17β-estradiol [13], and with trenbolone acet-
ate plus estradiol [14], or livers from beef cattle after ex-
perimental treatment with dehydroepiandrosterone [15].
More recently, the potentiality of RNA- sequencing tech-
nology for the detection of growth-promoters abuse in cat-
tle was explored and successfully used to screen for highly
regulated genes to be proposed as biomarker candidates
for detecting the treatment with trenbolone acetate plus
estradiol [16].
In the present study, the use of transcriptomics is
extended for the first time to unknown skeletal muscle
samples, collected directly from beef cattle immediately
after slaughtering. These samples are part of a larger survey
during which also thymus and urine specimens were col-
lected with the aim of detecting putative use of corticoster-
oids in commercial animals. Histological analyses on
thymic samples were used following a validated protocol to
classify samples as positive, suspect or negative for cortico-
steroid treatment and results have been reported previ-
ously [17], showing a relevant percentage of suspect
animals for corticosteroid treatment compared to officialTable 1 Confirmation data of DEX in spiked urine analyzed b
Analyte RR exp
a RRT req RRT passed Ion rat
DEX 1.389 1.354-1.423 Y 0.990
a Relative retention time (min).
b Area ratio of product ions from extracted ion chromatograms.data. Here, detection of DEX urinary excretion by Liquid
Chromatography - Mass Spectrometry (LC-MS) was add-
itionally implemented to provide direct evidence of illicit
use of anabolic steroids. All samples (LC-MS positive and
negative samples, positive, suspect or negative from histo-
logical analysis) were analyzed using a cattle-specific oligo-
DNA microarray and compared with known negative con-
trols. The goal of this study was to identify gene expression
patterns that could classify unknown commercial samples




LC-MS analyses were performed on urine from the
slaughtered animals to obtain an analytical confirmation
for the thymus histological results [17]. First, the LC-MS
method was validated and results of method validation
are summarized in Tables 1 and 2. The method valid-
ation process for DEX analysis consisted of the analysis
of 20 different blank urine samples in order to verify the
absence of target analyte and potential interfering com-
pounds. No interferences being detected in the analyte
diagnostic chromatograms. Figure 1 reports the
extracted ion chromatograms obtained from a blank
urine spiked with betamethasone (rt 15.9 min) and DEX
(rt 16.4 min) at 2.5 ng/ml, showing the ability of the
chromatographic method to separate the peaks of the
two isomeric corticosteroids so avoiding the possibility
of misrecognition. For all the analytes, the confirmation
of the identity according to Decision 2002/657/EC was
demonstrated by comparing the relative retention time
observed for the spiked analytes to the standards, fur-
thermore two granddaughters ions, with a signal to noise
greater than 3, were monitored and all ion ratios of sam-
ples were within the recommended tolerance when com-
pared with standards (Table 1).
The results of LC-MS3 analysis confirmed the pres-
ence of DEX residues in urine of the four animals posi-
tive for histological data (P21, P54, P56, P57; Figure 2,
Table 3). The concentration of DEX ranged from LOD
and 1.2 ng/ml.
Microarray analysis
Microarray experiments for all the 43 bovine skeletal
muscle samples were performed.
High quality, unbiased and reproducible gene expres-
sion data are always desirable in any DNA microarrayy LC-MS3
io exp
b Ion ratio req Ion ratio passed LOQ (ng/mL)
0.790-1.190 Y 0.25
Table 2 LC-MS3 validation
Analyte/parameter DEX
spike level (ng/ml) 0.25 0.50 2.50
repeatibility (R.S.D., %) 9.3 9.8 5.6
recovery (%) 89 92 110





Validation data for the determination of DEX in urine by LC-MS3 (n=18 at each
level).
Figure 2 Diagnostic ion chromatograms obtained from the
analysis of the urine sample P21. IS: internal standard; DEX:
Dexamethasone.
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tomics for the identification of illicit use of steroid hor-
mones, data quality becomes essential for obvious
reasons. Comparison of normalized, averaged spike-in
signals across different experimental replicates provided
a strong indication of the robustness of the normalization
process as spike-in variation across samples was minimal.
The filtering process on the basis of the second lowest
spike-in concentration resulted in removing 1,340 unique
transcripts. Finally, gene-specific quantitative (q) RT-
PCR assays were developed and used to quantify relative
expression of 10 genes in the whole set of samples.
As shown in Table 4, a positive and significant cor-
relation of expression values was found for all vali-
dated genes. The overall correlation of FC values
calculated for the two methods (qRT-PCR and DNA-
microarray) also showed a high correlation coefficient
(Spearman’s rho=0.87; P < 0.001).Figure 1 Specificity of the LC-MS method. Diagnostic ion
chromatograms obtained in bovine blank urine sample spiked with
2.5 ng/mL of betamethazone (retention time 15.9 min) and DEX
(retention time 16.4 min).After data extraction, normalization, and filtering, pro-
cessed signals for 20,155 unique transcripts in 43 muscle
samples were analyzed using PCA. The rationale for using
this exploratory statistical tool is based on the need to re-
duce the inherent multidimensionality of microarray data
and to avoid assumptions on the classification of the sam-
ples, without prior distinction between negative controls,
positive samples, and unknown commercial specimens.
The first two components, which account for a substantial
fraction (71.2%) of the total variance, clearly identified four
main groups (Figure 3A). Negative controls were broadly
distributed along the x-axis, which explained 42.8% of the
total variance. All the 13 Holstein samples were clustered
in group 1, while the remaining five known samples, all
cross-breed (Limousine × Charolais), were included in
group 2 (Figure 3A). Group 3 included all the four samples
(P21, P54, P56, P57) classified as positive for corticosteroid
treatment by both histological and LC-MS analyses and
the group 4 comprised exclusively samples collected at the
slaughterhouse. The two sets of controls were different also
with respect to age, as untreated animals in group 1 were
animals between 13 and 18 months old, those in group 2
were all 18 months old bulls. To explore the potential
association of breed (Holstein, Limousine, Charolais,
cross-breed) with the separation of samples along the two
principal axes, a one-way ANOVA was carried out using
breed as the discriminant variable and individual samples
PCA scores either on the x- or the y-axis as dependent
variable. A significant partition of samples along both axes















































a value > cut off factor.
b value < LOQ.
n.d.: not detected (< LOD).
Results from urine randomly collected at slaughterhouse.
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evidenced. After excluding Holstein samples, the other
breeds were homogenously distributed on both compo-
nents (x-axis F = 0.225 p = 0.8; y-axis F = 1.585 p =
0.223). Age of animals showed no significant correlation
with sample scores on the first component (Spearman
rho = 0.21 p = 0.20) and the second one (r = 0.16 p =
0.34). For a few animals the age was putatively approxi-
mated during veterinary inspection at the slaughterhouse.
Based on these results, the observed dispersion of
negative controls is likely to be attributable to the inclu-
sion of Holstein animals, which is a rather different
breed than the French breeds or their crosses that are
prevalent in the study. However, breed did not explain
the separation of all other samples. Two additional vari-
ables that are known to largely affect gene expression in
the skeletal muscle, gender and muscle type [18], could
be excluded as they were identical for all samples by ex-
perimental design.
To avoid possible distortion in the PCA plot due to breed
effects, Holstein samples were excluded from the subse-
quent analyses and the PCA was repeated (Figure 3B).
Here, the first two components, which account for 70.9% ofTable 4 Spearman’s rho for the set of selected genes
used for qRT-PCR validation
Gene Symbol Spearman’s rho FC qRT-PCR FC Array
AMPD1 0.881*** −4.0 −3.0
ANKRD35 0.923*** 1.9 2.5
BVLRB 0.598*** 1.5 2.8
DDIT4L 0.892*** −3.6 −5.5
GLUL 0.914*** −2.2 −2.3
HOXA9a 0.799*** −163.7 −111.9
MEN1 0.504** 1.2 2.0
NAT14 0.846*** 2.2 1.6
S100-B 0.902*** 1.8 2.0
SIRT3 0.876*** 1.8 2.4
a HOXA9 gene expression values evaluated by qRT-PCR in some suspected
samples were below the limit of detection and therefore arbitrary values were
assigned.
FC was calculated comparing group B vs group A animals.
**P < 0.01; ***P < 0.001.
Figure 3 PCA of the bovine skeletal muscle gene expression profiles. (A) PCA plot shows the two principal components of greatest
variation which cover 42.8% (x-axis) and 28.4% (y-axis) of the total variance. (B) PCA plot excluding Holstein samples; x-axis and y-axis cover 56.2%
and 14.7% of the total variance, respectively. Green triangles represent one set of controls (K, mixed-breed), green squares the second set of
controls (C, Holstein), red trapeziums the animals positive for corticosteroid treatment at histological analyses and LC-MS (P) and black circles the
unknown animals.
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explained 56.2% of variance, separated group A, which
included the negative controls and some unknown animals,
from group B, which comprised all four positive samples
and other unknown samples.
To evaluate the statistical significance of the observed
clustering, microarray data for the group B were com-
pared to the group A in a two-class unpaired data SAM
test. Even enforcing a stringent false discovery rate
(FDR, 0%) and a conservative fold-change (FC) threshold
(2-fold), a large number of differentially expressed genes(DEG) was obtained, with 2,351 up-regulated and 1,610
down-regulated transcripts (see Additional file 1 and
Additional file 2), suggesting a highly significant differ-
ence in expression profiles between group A and group
B in Figure 3B.
To explore the functional significance of the observed
difference, enrichment analysis of DEG was carried out
yielding several significantly enriched Gene Ontology (GO)
terms and KEGG pathways (Table 5). Different signaling
pathways (G-protein coupled receptor protein signaling
pathway, cell surface receptor linked signal transduction,
Table 5 GO Biological Process, GO Molecular functions and KEGG pathways analysis of differentially regulated genes
Category Term Count PValue FE
GO_BP_FAT G-protein coupled receptor protein signaling pathway 114 1.44E-05 1.446
GO_BP_FAT Cell surface receptor linked signal transduction 162 3.14E-05 1.328
GO_BP_FAT Regulation of transcription, DNA-dependent 125 0.014 1.200
GO_BP_FAT Regulation of RNA metabolic process 126 0.021 1.182
GO_BP_FAT tRNA thio-modification 4 0.022 5.332
GO_BP_FAT Regionalization 19 0.023 1.688
GO_BP_FAT Pattern specification process 23 0.030 1.552
GO_BP_FAT Anterior/posterior pattern formation 15 0.031 1.777
GO_BP_FAT Peptide transport 8 0.037 2.369
GO_BP_FAT tRNA wobble uridine modification 4 0.048 4.265
GO_BP_FAT tRNA wobble base modification 4 0.048 4.265
GO_BP_FAT Pancreas development 4 0.048 4.265
GO_BP_FAT Positive regulation of organelle organization 8 0.049 2.245
GO_CC_FAT Intrinsic to membrane 405 2.21E-05 1.157
GO_CC_FAT Integral to membrane 390 2.86E-05 1.160
GO_CC_FAT Myofibril 20 8.78E-05 2.511
GO_CC_FAT Contractile fibre 20 1.84E-04 2.400
GO_CC_FAT Sarcomere 17 4.27E-04 2.481
GO_CC_FAT Contractile fibre part 17 8.64E-04 2.354
GO_CC_FAT Intermediate filament cytoskeleton 18 0.003 2.025
GO_CC_FAT Intermediate filament 18 0.003 2.025
GO_CC_FAT I band 11 0.004 2.582
GO_CC_FAT Keratin filament 10 0.008 2.571
GO_CC_FAT Z disc 10 0.008 2.571
GO_CC_FAT Transcription factor complex 22 0.020 1.627
GO_MF_FAT Olfactory receptor activity 42 9.56E-04 1.629
GO_MF_FAT Calcium ion binding 95 0.004 1.292
GO_MF_FAT Passive transmembrane transporter activity 52 0.027 1.312
GO_MF_FAT Channel activity 52 0.027 1.312
GO_MF_FAT Substrate specific channel activity 51 0.028 1.312
GO_MF_FAT Ion channel activity 50 0.033 1.306
GO_MF_FAT Transcription factor activity 73 0.033 1.236
KEGG Olfactory transduction 54 2.24E-05 1.725
GO, Gene Ontology; BP: Biological Process; MF, Molecular Function; CC, cellular component; P value: modified Fisher exact P value calculated by DAVID software;
FE, Fold Enrichment defined as the ratio of the two proportions: input genes involved in a biological process and the background information.
DAVID functional annotation of the complete list of differentially regulated genes between group A and group B (see Figure 3B).
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regulated. In particular, the expression of several genes en-
coding odorant receptors (ORs) was significantly up-regu-
lated. ORs are expressed in several tissues, but their
function outside the olfactory epithelium is largely un-
known. However, it has been recently reported that ORs
might have a relevant role in myogenesis and muscle re-
generation. Griffin and colleagues [19] analyzed 18 OR
genes and found that 13 were up-regulated during myo-
genesis in primary cultured of mouse muscle cells. MostORs were over-expressed during myoblast fusion. In vivo
expression analysis of one OR (MOR23) demonstrated that
ORs have an important role during muscle regeneration,
guiding cell migration and fusion. In a previous study,
Carraro and colleagues [13] examined gene expression pro-
files of bulls administered with a sub-therapeutic dose of
DEX for 43 days in comparison with untreated controls.
Within the large set (835) of transcripts that were signifi-
cantly up-regulated in DEX-treated animals, several genes
were found to be involved in regulatory pathways that
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eration. Interestingly, the list of up-regulated genes in that
study included 13 OR-encoding genes [13], similar to what
observed in group B animals in the present work, which
showed up-regulation of 56 OR-coding genes.
Several sarcomere proteins were differentially regu-
lated as well. High doses of DEX were reported to lead
to muscle atrophy, mostly affecting fast twitching fibres
[20]. A recent study by Stella and colleagues [21], com-
paring protein expression profiles between beef cattle
treated with DEX, alone or in association with clenbu-
terol, using 2D protein gel electrophoresis and mass
spectrometry confirmed that the administration of DEX
favors a slow fiber phenotype. Stella and co-workers
reported that fast fiber specific proteins (e.g. myosin
light chain 1, myosin light regulatory chain 2, and iso-
form 3 of troponin T) and glycolytic enzymes were sig-
nificantly under-expressed in DEX-treated animals,
while myosin light chain 6B (MYL6B) alkali smooth
muscle and non-muscle and isoform 1 of troponin T
(TNNT1) were significantly over-expressed. In agree-
ment with such evidence, transcripts encoding TNNT1,
MYL6B, and myosin binding protein C slow type were
up-regulated in group B animals of the present work
while three glycolytic enzymes were significantly under-
expressed.
Different myosin isoforms (18B, 7B, 16, 9B), myosin
heavy chain 7 (MYH7), 15 (MYH15), 4 (MYH4), myosin
regulatory light chain interacting protein (MYLIP) and
myosin light chain kinase (MYLK) were up-regulated in
group B animals, supporting previous studies showing
that glucocorticoids can promote myogenic repair and
myoblast proliferation. In particular, while high doses of
glucocorticoids in vitro impair C2C12 myoblast prolifera-
tion rate and differentiation capacity, lower doses in-
crease the myogenic fusion efficiency of C2C12 cells [22].
Also ion channel activity was found to be modified be-
tween the two groups of animals. In particular, several
genes involved in calcium signaling pathways were up-
regulated. It has been reported that Ca2+-dependent cal-
cineurin signaling mediates skeletal muscle hypertrophy
upon stimulation with IGF1 or insulin associated with
DEX [23]. Calcineurin is a calcium-activated protein
phosphatase which, upon activation, transduces signal by
removing specific phophorylation of the cytoplasmic
transcription factor nuclear factor of activated T-cells
(NFAT). This allows NFAT translocation to the nucleus,
where it activates the transcription of IL-4, a cytokine
that has a key role in autocrine/paracrine control of
mammalian muscle growth [24]. In fact, IL-4 and IL-4
receptor were found to be over-expressed in group B
animals sampled at the slaughterhouse as well as in DEX-
treated bulls [13]. Muscle cell membrane depolarization
due to K+ efflux has also been reported to activatecalcineurin-mediated transcriptional responses [25]. Intri-
guingly, several potassium voltage-gated channels were
over-expressed in group B animals.
The putative similarity in the transcriptomic response
in the skeletal muscle of beef cattle after low-dose ad-
ministration of DEX [13] and in individuals clustering
within group B in the present study is statistically rele-
vant. Overall, 206 genes were up-regulated in both sets
of samples, showing a highly significant concordance
(Fisher Exact test, p < 0.0001). A few “common” tran-
scripts are worth mentioning. Colony stimulating factor
3 receptor (CSF3R) is part of the JAK1-STAT1-STAT3
pathway, which was reported to induce myoblast prolif-
eration [26]. Protein phosphatase 2 (PP2), whose regula-
tory subunit PP2R1A and catalytic subunit isoform
PPP2CA were up-regulated, has an activating role in
Wnt signaling, a pathway that was shown to be asso-
ciated with satellite cell proliferation during muscle re-
generation [27]. Actin-related protein 2/3 complex
subunit 1A (ARPC1A) is part of a complex that has a
critical role in myoblast fusion during either muscle de-
velopment or regeneration [28]. Elevated expression of
Delta-like 1 (DLK1) contributed to hypertrophy in calli-
pyge sheep skeletal muscle [29], while experimental
over-expression of DLK1 in mouse skeletal muscle
induced hypertrophy [30]. The highly significant concord-
ance with gene expression modifications reported in DEX-
treated cattle suggests that all animals of group B might
have been illegally administered with DEX. This can ex-
plain, at least in part, the observed marked difference in
gene expression profiles between group A and group B.
Gene expression data from positive samples and nega-
tive controls were also analyzed to evaluate the ability to
classify unknown samples with a reduced set of inform-
ative markers, using a statistical approach for class pre-
diction implemented in the Prediction Analysis of
Microarrays (PAM) software. PAM has been extensively
applied to classify cancer types based on individual
tumor expression profiles. It uses the method of nearest
shrunken centroids to find out the minimal set of genes
that provides the greatest accuracy of class prediction.
The program first performs a discriminant analysis on
“known” samples (Training Sample Set) to choose the
smallest panel of genes that provide the greatest accur-
acy of class prediction (the smallest misclassification
error). In the present study, the training set consisted of
9 samples, representing two classes, negative and posi-
tive. For the former class, the 5 cross-breed control ani-
mals were included. For the latter, the 4 samples (P21,
P54, P56, P57) that were classified as positive by LC-MS
and thymus histological analyses. PAM allowed to
exactly discriminate the two classes using only two genes
(importin 9, propionyl-CoA carboxylase beta chain,
mitochondrial precursor). The accuracy of class
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was then estimated through cross-validation (10% of
samples were randomly extracted and classified based
on the discriminant function calculated on the
remaining cases). Figure 4A shows that 100% accuracy
was obtained for cross-validation. Finally, the two genes
were used to classify all the samples (Test Sample Set)
not included in the training set (21 commercial sam-
ples). All animals originally clustering in group A were
classified as negative, whereas all individuals in group B
were predicted as putative positive (Figure 4B).
Discussion
Two main findings were observed in the present study.
First, broad variation in gene expression profiles exists
across both known and unknown samples. The causes of
such variation are not completely clear, although breed
appeared to be the most important. This observation
reinforces the obvious, yet often overlooked, need for a
most comprehensive representation of biological vari-
ation, when indirect biomarkers are applied outside con-
trolled experimental settings. Second, after removing theFigure 4 Plot of cross-validated probabilities and test
probabilities for sample classification. (A) On x-axis individual
samples: 1–5 negative controls, 6–9 samples positive at histological
and LC-MS analyses; on y-axis the probability of being classified as
controls (circles) or positive (rectangules). (B) On x-axis individual
samples; on y-axis the probability of being classified as negative
(circles, 1) or positive (rectangules, 2).main source of variation, unsupervised analysis of gene
expression profiles showed a highly significant distinc-
tion between two groups, one including positive controls
and a sub set of commercial samples, the other compris-
ing all negative controls and the remaining unknown
individuals. The observed separation was confirmed by a
two-class SAM test that identified over 3,900 differen-
tially expressed genes and a class prediction approach
that was able to discriminate between the two groups
using just two genes, using as a training set positive and
negative controls and as test set all unknown samples.
Functional annotation of up- and down-regulated tran-
scripts showed several biological processes and molecu-
lar pathways that have been already reported in previous
proteomic and transcriptomic studies to be altered upon
controlled administration of low dosage corticosteroids.
Such evidence seems to suggest that unknown animals
clustering with LC-MS positive samples might have been
administered with glucocorticoids as well. It cannot be
completely excluded that all unknown samples in group
B showed a transcriptomic profile similar to positive
controls for other reasons than being treated with ana-
bolic hormones. On the other hand, such explanation
appears quite unlikely as both technical issues (e.g. sys-
tematic bias in microarray data) and biological variables
known to affect gene expression profiles have been care-
fully controlled. Therefore, under the working hypoth-
esis that group B samples should considered as suspect,
how such hypothesis could be reconciled with the more
limited evidence of positive animals (LC-MS) or suspects
(histology)? With regard to LC-MS results, one possible
explanation is related to the fact that DEX or other cor-
ticosteroids are often illegally administered as diluted so-
lution spread on feed and differences in drug uptake can
be evidenced across treated animals. Such very low
dosages and the rapid metabolism and excretion of these
substances make determination of residues extremely
difficult [31], even by using targeted GC/MS and LC/
MS/MS methods [32-39]. The urinary parent compound
and its metabolites concentration are very low during all
the treatment time and completely absent a short time
after the interruption of the treatment [40], while bio-
logical effects, including transcriptomic responses, might
still be detectable as such effects are caused by anabolic
compounds and often persist after the hormone has
been eliminated. It is also well-known that corticoster-
oids are administered as cocktails of different chemical
species with similar biological action to reduce the
amount of single compounds. This could make LC-MS
less sensitive. In particular, when targeted LC-MS ana-
lyses are carried out, for instance searching for DEX,
sensitivity is decreased when DEX is not the major com-
ponent of the cocktail or is entirely substituted with
other corticosteroids. With regard to the results of
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four samples could be reliable considered as putative
positive, others were considered dubious, including
some those included in group B. In fact, the efficacy of
the histological method has been recently challenged be-
cause of the lack of appropriate reference material con-
sidering the evolving nature of animal-rearing practices
[41]. Furthermore, administration of corticosteroids
leads to thymus cortical atrophy and ‘starry sky’ appear-
ance. However, age-associated thymic involution was
evidenced in cattle as in other mammals. As the animals
included in the present study were mostly all over 12
months old and most around 15–18 months of age, sev-
eral positive cases might have been considered negative
or dubious because natural thymic involution could not
be distinguished from the effects of corticosteroid treat-
ment. On the other hand, the biological effects of corti-
costeroids on gene expression data were proved to
persist several days after time of withdrawal [11,12,42]
and thus may evidence the anabolic treatments even
when the active compound and its metabolites have
been excreted and they are no longer detectable, as men-
tioned above.
If the working hypothesis of all animals in group B
being putative positive were correct, the number of sus-
pect cases would be quite impressive. However, the ac-
tual importance of growth-promoter abuse in beef cattle
is known to be underestimated [43] because highly in-
formative analytical methods are used on just a small
number of cases and often such methods are not sensi-
tive enough to detect residues of low dosage cocktails.
This prompts for the development and use of more reli-
able and cost effective screening tools.
Conclusions
The present work showed that it might be possible to
use just a few gene markers for highly reliable sample
classification. However, global transcriptomic tools
(DNA microarrays, RNA-seq) are becoming increasingly
affordable and rapid, and soon a whole-transcriptome
analysis will be feasible in routine practice. Such an ap-
proach avoids a priori selection of candidate markers,
allows the identification of complex transcriptomic sig-
natures through functional annotation and enables the
comparison with other -omic and analytical/chemical
studies. This will lead toward meta-analysis of data from
controlled experiments as well as field studies and in
turn, to the identification of indirect biomarkers less
influenced by unknown variables.
Methods
Animals and sampling
Tissue samples from a specific anterior limb muscle (Biceps
brachii) were collected, immediately after slaughtering,from 25 beef cattle randomly selected in 10 different
batches and stored in 2 mL RNAlater solution (Ambion,
Monza, Italy) at −20°C until extraction. Urine samples were
collected during slaughtering from the bladder and each
sample, without any preservative, was divided in 15 mL ali-
quots and stored at −20°C until the analysis. Sample collec-
tion was part of a monitoring program on anabolic
treatment targeted on indirect biomarkers. The sampling
was managed by the Regional Veterinary authorities
(Veneto, Italy) and carried out by trained veterinarians.
The animals were vaccinated against the main respiratory
diseases and treated regularly against parasites typical of
the species. They were healthy at ante-mortem inspection,
passed post-mortem inspection, and their meat was
approved for human consumption. All individuals were
male, their age ranged between 12 and 24 months, and
weight between 300–500 kg. The majority of the commer-
cial samples were Charolais, Limousine, or mixed breed
(Charolais×Limousine).
Two additional sets of samples from previous con-
trolled experiments were included as negative controls: one
set included 5 samples from mixed-breed (Charolais×
Limousine) 18 months old male bulls, ~450 kg mean body
weight, while the second one included 13 samples from
male Holstein beef cattle between 13 and 18 months old,
500–670 kg body weight. The control animals came from
experiments conducted according to the guidelines of Ital-
ian law (DL 116/92) and European legislation (11 and sub-
sequent amendments) for care and use of experimental
animals, and the studies were approved by the Italian Min-
istry of Health ethical committee.
LC-MS analysis
Chemicals
All solvents for LC-MS were HPLC or analytical grade
and purchased from Carlo Erba Reagenti (Milan, Italy).
The water used was purified using a Milli-Q system
(Millipore, Bedford, MA, USA). Sodium acetate trihy-
drate and the enzyme for phase II metabolite deconjuga-
tion (Helix pomatia preparation) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Dexamethasone
was purchased from Steraloids (Newport, RI, USA).
Cortisol-d4 (internal standard) was obtained from CDN
Isotopes (Pointe-Claire, Quebec, Canada).
Standard solution
Stock solutions of reference standard (1 mg/mL) were
prepared in methanol; working solution (1 μg/mL and
0.1 μg/mL) were prepared, monthly, by successive tenfold
dilution with methanol and stored in the dark at −20°C.
Standard curves were prepared daily by dilution of
working solution in water–methanol-formic acid
(50:50:0.1, v:v:v) to obtain seven concentration levels
ranging from 0.1 to 25 ng/mL.
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After centrifugation, a 5 mL aliquot of urine was spiked
with 25 μL of the internal standard solution (1 μg/mL).
The pH was adjusted to approximately 5 by adding 15
ml of 1 M pH 5 acetate buffer, then 50 μL of Helix
pomatia juice was added to the sample and enzymatic
hydrolysis was carried out overnight at 40°C. The prep-
aration was repeated on two separated aliquots, includ-
ing or omitting the Helix pomatia preparation addition
and incubation.
Subsequently, 16 mL of the sample was applied to Strata
C18-U SPE cartridges (500 mg, Phenomenex, Bologna,
Italy) previously activated with 5 mL of methanol and 5 mL
of water. After washing with 5 mL of water and 10 mL of
methanol–water (20:80, v/v), analytes were eluted with
2 ml of methanol. Then, the extract was applied to Strata
NH2 cartridges (100 mg, Phenomenex, Bologna, Italy),
previously activated with 1 mL of methanol. Purified
extracts were evaporated and reconstituted in 500 μL of
water–methanol-formic acid (50:50:0.1, v:v:v).
Liquid chromatography
An Accela 600 HPLC pump with CTC automatic in-
jector was used (Thermo Fischer Scientific, San Jose,
CA, USA). Reversed-phase liquid chromatography was
performed on a 100 × 2.1 mm i.d., 1.9-μm Thermo
Hypersil Gold column. The mobile phases consisted of
(A) 0.1% formic acid (v/v) in water and (B) 0.1% formic
acid in methanol. The mobile phase composition (A:B; v/v)
was: 90:10 at 0 min, 10:90 at 21 min, and 90:10 from 22 to
25 min; the flow rate was set at 200 μL/min. The sample
trays was maintained at 4°C. A sample volume of 10 μL
was injected.
Mass spectrometry
Mass spectrometric analysis was performed on a LTQ
XL ion trap (Thermo Fischer Scientific, San Jose, CA,
USA), equipped with a heated electrospray ionization
(HESI-II) probe operating in negative ion mode with the
following condition: sheath and auxiliary gas (nitrogen)
flow 30 and 10 arbitrary units, respectively; ion spray
voltage 2 kV; capillary temperature 275°C; capillary volt-
age −13 V; tube lens −68 V. Helium was used for
collision-induced dissociation.
As already reported [44], in ESI- corticosteroids give
an abundant and unique adduct with the conjugatedTable 6 Molecular weights and diagnostic ions of the investig
compound MW P.I.(m/z) [M+COOH]- C.E. MS2
Dexamethasone 392 437 15
Cortisol-d4 (IS) 364 411 12
C.E. collision energy % - P.I. precursor ion.
a quantifier ion. b identifier ion.base of the organic acid used; two product ions were
obtained employing the formate adduct [M+COOH]- as
precursor ion for MS2: the pseudomolecular ion [M-H]-
and the fragment [M-CH2O-H]
- which was indicated as
corresponding to cleavage of the C21 side chain with
loss of formaldehyde [45]. As the [M-H]- ion was not
specific, the [M-CH2O-H]
- ion was used as precursor for
MS3 to have additional diagnostic ions to obtain a full
identification of the analytes. To perform MS2 and MS3,
the precursor isolation was set to 2 Da; precursor ions,
product ions and collision energies are shown in
Table 6.
Xcalibur (version 2.1) data acquisition software from
Thermo was used.Calibration and quantification
Calibration lines were constructed using pooled urine
obtained from samples collected during several experi-
mental plans from bovine of different age and breed.
Pooled urine samples, with no residues of DEX, were
spiked with 2.5 ng/mL of IS and with DEX to obtain a
concentration range of 0.2-10 ng/mL.
Quantification was based on peak area ratios of the
analyte to the IS and a least-squares linear regression
analysis was performed to calculate calibration curves.Method validation
The validation study was carried out at three concentra-
tion levels by the analysis of pooled urine samples spiked
with 0.25, 0.50 and 2.5 ng/ml of DEX. To each sample
2.5 ng/mL of the I.S. cortisol-d4 was added, and six
replicates of each sample were analyzed on three differ-
ent days to evaluate the recovery (internal standard cor-
rected) and the precision in term of repeatability (within
day) and within laboratory reproducibility (different
operators and environmental conditions).
For DEX, the limit of detection (LOD) was calculated
as the mean plus three times the standard deviation of
the signal-to-noise ratio of 20 representative blank urine
samples; the limit of quantification (LOQ) was calcu-
lated as the mean plus ten times the standard deviation
of the signal-to-noise ratio of 20 representative blank
urine samples; the decision limit (CCα) and the detec-
tion capability (CCβ) were calculated according to the
ISO standard 11843 [46].ated corticosteroids
P.I. (m/z) MS2 C.E. MS3 Product ion (m/z) MS3
361 20 292,307 b,325,345 a
335 - -
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RNA extraction
Total RNA was extracted from 30 mg tissues using the
RNeasy Mini kit (Qiagen, Hilden, Germany) according to
the manufacturer’s instructions. The concentration of
RNA samples will be measured using a UV–vis spectro-
photometer NanoDrop ND-1000 (Nanodrop Technolo-
gies, Wilmington, DE) and RNA a was estimated running
each sample on a RNA-chip in an Agilent 2100 Bioanaly-
zer (Agilent Technologies, Palo Alto, CA). RNA integrity
number (RIN) index was evaluated using the Agilent 2100
Expert software. RIN is a numerical assessment of the in-
tegrity of total eukaroyte RNA samples based on the entire
electrophoretic trace of the RNA sample rather than the
ratio of the ribosomal bands and allows to standardize the
interpretation of RNA quality. In the present study a con-
servative threshold was enforced in order to reduce ex-
perimental biases due to poor RNA quality. To ensure
optimal data quality, only RNA samples with RIN number
≥7.0 were included in the analysis as suggested by proto-
cols for microarray experiments.
RNA amplification, labeling and hybridization
Sample labeling and hybridization were performed
according to the Agilent One-Color Microarray-Based
Gene Expression Analysis protocol. Briefly, for each
sample 200 ng of total RNA were linearly amplified and
labeled with Cy3-dCTP. A mixture of 10 different viral
poly-adenilated RNAs (Agilent Spike-In Mix) was added
to each RNA sample before amplification and labeling,
to monitor microarray analysis work-flow. Labeled
cRNA was purified with Qiagen RNeasy Mini Kit, and
sample concentration and specific activity (pmol Cy3/μg
cRNA) were measured in a NanoDrop ND-1000 spec-
trophotometer. A total of 1,650 ng of labeled cRNA was
prepared for fragmentation adding 11 μL 10× Blocking
Agent and 2.2 μL of 25× Fragmentation Buffer, heated at
60°C for 30 min, and finally diluted by addition with
55 μL 2× GE Hybridization buffer. A volume of 100 μL
of hybridization solution was then dispensed in the gas-
ket slide and assembled to the microarray slide (each
slide containing four arrays). Bovine-specific oligo-arrays
(Agilent Bovine-Four-Plex G2519F) were used. For most
of the transcripts represented on this array, two identical
probes are synthesized at two distinct positions on the
slide, therefore the average value between the intensities
of the two replicate probes was used. The slides were
incubated for 17 h at 65°C in an Agilent Hybridization
Oven, subsequently removed from the hybridization
chamber, quickly submerged in GE Wash Buffer 1 to
disassembly the slides and then washed in GE Wash
Buffer 1 for approximately 1 minute followed by one
additional wash in pre-warmed (37°C) GE Wash Buffer
2. Hybridized slides were scanned at 5 μm resolutionusing an Agilent G2565BA DNA microarray scanner.
Default settings were modified to scan the same slide
twice at two different sensitivity levels (XDR Hi 100%
and XDR Lo 10%). Microarray data have been deposited in
NCBI's Gene Expression Omnibus [47], and are accessible
through GEO Series accession number GSE26318.
Normalization of microarray data
The two linked images generated from the scanned slide
were analyzed together, data were extracted and back-
ground subtracted using the standard procedures con-
tained in the Agilent Feature Extraction (FE) Software
version 9.5.1. The Feature Extraction software returns a
series of spot quality measures that enable to evaluate
goodness and reliability of spot intensity estimates. Add-
itionally, in each sample, spike-in viral poly-adenilated
RNAs were added before sample processing to provide
an internal quality control. Each spike-in RNA has a dif-
ferent known concentration following a dilution series
and there are 32 replicate probes for each spike-in RNA
on the array. All samples (negative, positive, and un-
known samples) were then normalized together in a sin-
gle run to avoid potential biases. After normalization,
spike intensities are expected to be uniform across the
experiments of a given dataset. Based on the comparison
of spike-in probe signal between arrays after normalization,
cyclic loess approach was chosen. All control features ex-
cept for Spike-in (Spike-In Viral RNAs) were excluded
from subsequent analyses. After normalization, a further
quality control step was performed by removing all probes
with intensity values lower than the second lowest spike-
in concentration because this value was considered too
close to the limit of detection. So, probes with intensity
values <4 in at least 30 of the 43 samples were removed
from the dataset. Filtering and normalization procedures
were performed using R statistical software available at
http://www.r-project.org/.
Quantitative (q)RT-PCR
A set of 10 genes (see Additional file 3) was validated by
real-time RT-PCR. This validation step provided independ-
ent validation of microarray data. For each selected target
gene and for the reference gene (RS5), a (q)RT-PCR assay
was designed. Gene–specific primers that encompass one
intron were defined for each transcript (except for HOXA9
gene) using the program Primer Express version 2. To de-
sign intron-spanning primers, putative intron-exon bound-
aries were deduced from the Genome Browser Database
(http://genome.ucsc.edu/cgibin/hgGateway?hgsid=1050818
52&clade=vertebrate&org=Cow&db=0).
One microgram of the total RNA for each sample was
reverse transcribed to cDNA using Superscript II (Invitro-
gen, Milan, Italy). An aliquot (2.5 μL) of diluted (1:50 or
1:100) cDNA template was amplified in a final volume of
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2X qPCR Master Mix (Kapa Biosystems, Inc., Woburn,
MA, USA), 0.25 μL of each gene specific primer (10 μM).
The amplification protocol consisted of an initial step of
2 min at 95°C, followed by 45 cycles of 3 s at 95°C and 40 s
at 60°C. All experiments were performed in a LightCycler
480 instrument (Roche Diagnostics, Milan, Italy). To evalu-
ate the efficiency of each assay, standard curves were
obtained amplifying two-fold serial dilutions of the same
cDNA, which was used as calibrator. For each sample, the
Crossing Point (Cp) was used to determine the relative
amount of target gene; each measurement was made in du-
plicate and normalized to the reference gene RS5, which
was measured in duplicate as well.
Statistical analyses
PCA on normalized and filtered gene expression data was
carried out using the TMEV suite [48,49]. Sample classifi-
cation into two classes was based on visual inspection of
PCA plots. A two-class non parametric test for unpaired
data was implemented in the program SAM [50], to iden-
tify differentially expressed genes between classes, enfor-
cing a FDR of 0% and a FC of 2. Sample class prediction
was carried out using the program PAM [51], available on-
line at http://www.stat.stanford.edu/~tibs/PAM. All other
statistical tests (ANOVA, Spearman rank correlation
test, Fisher exact test) were carried out in R using the
RCommander GUI [52].
Functional annotation
Enrichment analysis on differentially up- and down-
regulated genes was performed using the Functional Anno-
tation tool available in the DAVID Database (http://david.
abcc.ncifcrf.gov/). GO terms and KEGG pathways included
in the DAVID knowledgebase were considered. For KEGG
terms, the following parameters were used: gene count 4,
ease 0.05. For GO Biological Process, Cellular Component
and Molecular Function BP_FAT, CC_FAT, MF_FAT re-
spectively, with gene count 4, ease 0.05 were used.
Additional files
Additional file 1: Table of the up-regulated genes identified by
SAM analysis.
Additional file 2: Table of the down-regulated genes identified by
SAM analysis.
Additional file 3: Table of genes and primers used in the Real-time
PCR validation assays.
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